Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × durvalumab × Sarcoma × Clear all

Phase

Phase 2 8 Phase 1 2 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 41 Gastrointestinal 14 Genitourinary 9 Gynecologic 4 Head & Neck 3 Breast 2 Tumor-Agnostic 1 Sarcoma 1 Other solid neoplasm 1

Conditions

Sarcoma 1 Neoplasm Metastasis 1

Interventions

Doxorubicin 37 Vincristine 25 Radiotherapy 25 Ifosfamide 25 Cyclophosphamide 21 Etoposide 18 Imatinib Mesylate 17 Radiation 12 Dactinomycin 12 Filgrastim 11 Temozolomide 9 Trabectedin 8 Sunitinib 8 Methotrexate 8 Specimen Handling 6 Granulocyte Colony-Stimulating Factor 6 pazopanib 5 Zoledronic Acid 5 Magnetic Resonance Spectroscopy 5 Irinotecan 5 Cisplatin 5 nilotinib 4 Topotecan 4 Surgical Procedures, Operative 4 Procarbazine 4 Paclitaxel 4 Liposomes 4 Ibandronic Acid 4 Dexrazoxane 4 Cytarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡